Global Dextran 40 Glucose Injection Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Intramuscular Injection and Intravenous Injection), By Application (Thrombosis, Hypovolemia, and Others), By End-User (Clinics, Hospitals, Ambulatory Surgical Centers, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Dextran 40 Glucose Injection Market Insights Forecasts to 2033

• The Global Dextran 40 Glucose Injection Market Size was estimated at USD 1.15 Billion in 2023
• The Market Size is expected to Grow at a CAGR of around 6.00% from 2023 to 2033
• The Worldwide Dextran 40 Glucose Injection Market Size is expected to reach USD 2.06 Billion by 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Dextran 40 Glucose Injection Market Size is anticipated to exceed USD 2.06 Billion by 2033, growing at a CAGR of 6.00% from 2023 to 2033.

Market Overview

The dextran 40 glucose injection market is a part of the pharmaceutical industry that focuses on intravenous solutions containing dextran 40, a bacterial fermentation polysaccharide, combined with glucose, used to treat hypovolemia and enhance plasma volume in critical care circumstances. Dextran is a synthetic colloid made of glucose polymers derived from Leuconostoc mesenteroides action on sucrose. It is supplied in 10% dextran 40 (40 kDa) and 6% dextran 70 (70 kDa) formulations, is sterile and nonpyrogenic, and is given through intravenous infusion. Dextran 40 is an odourless and tasteless white powder that lacks a crystalline structure. It does not dissolve easily in diethyl ether and ethanol, but it dissolves gradually in water. The injection of dextran 40 is a water-based solution with a dextran 40 concentration of 9.5 to 10.5 w/v%. It serves as a plasma volume expander in medical treatment procedures, particularly for addressing complexities such as hypovolemic shock and enhancing circulation, notably in microcirculation. It is also utilized in specific surgical operations to prevent blood clotting and enhance blood flow. Dextran 40 raises osmotic pressure within blood vessels, drawing water into the bloodstream. This is vital in instances of severe dehydration or blood loss. The marketed product of the dextran 40 glucose injection is MICROSPAN-40.

Dextran 40 glucose injections are used in the management of thromboembolic disorders, which is the first line of treatment recommended by healthcare professionals. The rising prevalence of thromboembolic disorders escalates the need for the dextran 40 glucose injection, which results in the expansion of the market. For instance, venous thromboembolism (VTE), a blood clot, affects up to 900,000 US people annually, with high risk during hospitalization, cancer treatment, and pregnancy. An estimated 60,000-100,000 Americans die from VTE each year, and many suffer long-term complications. Chronic illnesses such as diabetes and cardiovascular diseases also lead to a higher usage of these injections in the event of complications. Socioeconomic factors, including the increasing elderly demographic and the high incidence of chronic illnesses, also propel the market.

Report Coverage

This research report categorizes the global dextran 40 glucose injection market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global dextran 40 glucose injection market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global dextran 40 glucose injection market.

Driving Factors:

The dextran 40 glucose injection market is expanding due to the rising incidence of circumstances such as hypovolemia and thrombosis that necessitate plasma volume expanders. Technological advancements in drug formulation and delivery have rendered these injections more effective and safer. The susceptibility of older adults to these conditions further drives market growth. Improvements in healthcare infrastructure and access to emergency treatments also contribute to this expansion. Additionally, the growing occurrence of accidents and natural disasters increases the demand for emergency treatments involving plasma expanders. The anticoagulant activity of the dextran 40 injection is essential for the prevention and management of thrombosis. Following the enhancement of healthcare infrastructure worldwide, particularly in developing areas, access to medical treatments such as dextran 40 glucose injection is anticipated to increase. Advanced treatments are becoming more accessible to a wider population due to increased healthcare spending and improved insurance coverage.

Restraining Factors

The high cost of injection may be prohibitive for patients, particularly in underdeveloped nations with minimal healthcare budgets. The development of the market may also be hampered by the availability of substitute therapies, such as volume expanders and crystalloids, that may restrict the growth of the market.

Market Segmentation

The global dextran 40 glucose injection market share is classified into product type, application, and end-user.

• The intravenous injection segment dominated the global dextran 40 glucose injection market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the product type, the global dextran 40 glucose injection market is categorized into intramuscular injection and intravenous injection. Among these, the intravenous injection segment dominated the global dextran 40 glucose injection market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is facilitated by the rapid onset of action, avoids first-pass metabolism of the dextran 40, enhanced bioavailability (100%), accurate dosing, flexibility, directly goes to the systemic circulation, decreased irritation at the site of injection, long-term management, and ability to administer the complex pharmaceutical active ingredients.

• The hypovolemia segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the application, the global dextran 40 glucose injection market is categorized into thrombosis, hypovolemia, and others.  Among these, the hypovolemia segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is attributed to the reduced blood volume, increasing prevalence of hypovolemia, effective treatment against hypovolemia, advancements in medical technology, rising proportion of the geriatric population, and increasing cases of trauma.

• The hospitals segment held the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the end-user, the global dextran 40 glucose injection market is categorized into clinics, hospitals, ambulatory surgical centers, and others. Among these, the hospitals segment held the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is owing to the growing magnitude of surgical procedures, increasing in-patient services, rising emergency procedures, developed healthcare infrastructure, increasing prevalence of chronic conditions, and advancement and availability of sophisticated medical devices in hospitals.

Regional Segment Analysis of the Global Dextran 40 Glucose Injection Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global dextran 40 glucose injection market over the predicted timeframe.

North America is anticipated to hold the largest share of the global dextran 40 glucose injection market over the predicted timeframe. The advanced healthcare infrastructure, high healthcare costs, and growing provider awareness are the main factors driving the market for dextran 40 glucose injection in North America. The market is growing as a result of major pharmaceutical companies and continuous research and development. It is anticipated that an aging population and the increasing incidence of diseases like thrombosis and hypovolemia will fuel demand. Better formulations have increased the effectiveness and shelf life of dextran 40 glucose injection, increasing its dependability in critical care situations. There is an increasing need for efficient plasma volume expanders due to the aging population and chronic illnesses. Continuous investment in research and development improves the safety and effectiveness of injections based on dextran, while strict FDA standards guarantee safe and high-quality formulations.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. The Asia-Pacific region is expanding significantly as a result of investments in healthcare facilities, more medical tourism, and improved healthcare infrastructure. China, India, Japan, and other emerging markets have a sizable population and better access to medical care. Market expansion is anticipated as a result of government initiatives to enhance healthcare quality and accessibility. In addition, the region's aging population is driving up demand for efficient therapies. More affordable sophisticated medical treatments and improved healthcare facilities are made possible by economic development in nations like China and India. dextran 40 glucose injection and other medical items are produced and distributed in South Korea, Japan, and India owing to favorable regulatory policies.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global dextran 40 glucose injection market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Grifols, S.A.
• Amgen Inc.
• Sanofi S.A.
• B. Braun Melsungen AG
• Baxter International Inc.
• Hospira, Inc.
• Boehringer Ingelheim GmbH
• Novartis AG
• Roche Holding AG
• Merck & Co., Inc.
• Abbott Laboratories
• Otsuka Pharmaceutical Co., Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In September 2024, The U.S. Food and Drug Administration (FDA) approved Pfizer's emergency application to extend the Use Date for one lot of 10% LMD in 0.9% Sodium Chloride Injection (Dextran 40 in Sodium Chloride Injection) USP, NDC 0409-7419-03, and one lot of 10% LMD in 5% Dextrose Injection (Dextran 40 in Dextrose Injection) USP, NDC 0409-7418-03 to address a shortage of these vital products.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global dextran 40 glucose injection market based on the below-mentioned segments:

Global Dextran 40 Glucose Injection Market, By Product Type

• Intramuscular Injection
• Intravenous Injection

Global Dextran 40 Glucose Injection Market, By Application

• Thrombosis
• Hypovolemia
• Others

Global Dextran 40 Glucose Injection Market, By End-User

• Clinics
• Hospitals
• Ambulatory Surgical Centers
• Others

Global Dextran 40 Glucose Injection Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa